Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 295

1.

Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.

Markel G, Cohen-Sinai T, Besser MJ, Oved K, Itzhaki O, Seidman R, Fridman E, Treves AJ, Keisari Y, Dotan Z, Ramon J, Schachter J.

Anticancer Res. 2009 Jan;29(1):145-54.

2.

Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.

Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, Eberlein TJ.

J Clin Oncol. 1995 Aug;13(8):1939-49.

PMID:
7636534
3.

Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.

Mulders P, Tso CL, Pang S, Kaboo R, McBride WH, Hinkel A, Gitlitz B, Dannull J, Figlin R, Belldegrun A.

J Immunother. 1998 May;21(3):170-80.

PMID:
9610908
5.

Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.

Hayakawa K, Salmeron MA, Parkinson DR, Markowitz AB, von Eschenbach AC, Legha SS, Balch CM, Ross MI, Augustus LB, Itoh K.

J Immunother (1991). 1991 Oct;10(5):313-25.

PMID:
1790139
6.

Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.

Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Levêque J, Guillé F, Patard JJ, Lesimple T, Catros-Quemener V.

Eur Cytokine Netw. 2000 Jun;11(2):217-24.

PMID:
10903800
7.

Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.

Nishimura T, Terashima Y, Hattori T, Satoh M, Kondo Y, Kimura G, Yoshida K, Akimoto M.

Urol Int. 1991;47 Suppl 1:83-5.

PMID:
1949387
8.

Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.

Belldegrun A, Tso CL, Kaboo R, Pang S, Pierce W, deKernion JB, Figlin R.

J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):149-61.

PMID:
8732698
9.

Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.

Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S.

J Clin Oncol. 1997 Feb;15(2):796-807.

PMID:
9053507
10.

T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.

Leisegang M, Turqueti-Neves A, Engels B, Blankenstein T, Schendel DJ, Uckert W, Noessner E.

Clin Cancer Res. 2010 Apr 15;16(8):2333-43. doi: 10.1158/1078-0432.CCR-09-2897. Epub 2010 Apr 6.

11.

Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.

Bukowski RM, Sharfman W, Murthy S, Rayman P, Tubbs R, Alexander J, Budd GT, Sergi JS, Bauer L, Gibson V, et al.

Cancer Res. 1991 Aug 15;51(16):4199-205.

12.

Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.

Finke JH, Rayman P, Hart L, Alexander JP, Edinger MG, Tubbs RR, Klein E, Tuason L, Bukowski RM.

J Immunother Emphasis Tumor Immunol. 1994 Feb;15(2):91-104.

PMID:
7907918
13.

Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.

Kausche S, Wehler T, Schnürer E, Lennerz V, Brenner W, Melchior S, Gröne M, Nonn M, Strand S, Meyer R, Ranieri E, Huber C, Falk CS, Herr W.

Cancer Res. 2006 Dec 1;66(23):11447-54.

14.

Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.

Meijer SL, Dols A, Urba WJ, Hu HM, Smith II JW, Vetto J, Wood W, Doran T, Chu Y, Sayaharuban P, Alvord WG, Fox BA.

J Immunother. 2002 Jul-Aug;25(4):359-72.

PMID:
12142559
15.

The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma.

Steger GG, Gnant MF, Djavanmard MP, Mader RM, Jakesz R, Pierce W, deKernion JB, Figlin R, Belldegrun A.

J Cancer Res Clin Oncol. 1997;123(6):317-24.

PMID:
9222297
16.
17.

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.

Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG.

J Clin Oncol. 2003 Mar 1;21(5):884-90.

PMID:
12610189
18.
20.

Phenotypic and functional analysis of tumour-infiltrating lymphocytes from patients with renal cell carcinoma.

Thiounn N, Mathiot C, Tartour E, Joyeux I, Peyret C, Brandely M, Deslignieres S, Debré B, Fridman WH.

Eur Urol. 1994;25(2):151-7.

PMID:
8137857
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk